Alivus Life Sciences delivered robust financial performance in the quarter ended June 2026, with net profit surging 31.71% to ₹160.08 crore compared to ₹121.54 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's strong operational efficiency and market positioning during the quarter. The company's Earnings Per Share (EPS) increased to ₹13.04 in Q1 FY27, reflecting improved profitability and shareholder value creation.
The company's sales revenue increased 6.41% to ₹640.41 crore in Q1 FY27, up from ₹601.85 crore recorded in the same quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates steady business expansion and market demand for the company's products and services during the quarter. The company remains focused on APIs as its core business segment, positioning it well in the pharmaceutical API market.
The company's operating profit margin (OPM) improved to 33.06% in the June 2026 quarter, compared to 28.63% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin expansion reflects enhanced operational efficiency and better cost management during the quarter. The company's statutory changes impacted prior year results, but the current quarter demonstrates strong operational performance with no material misstatements in the financial review.
PBDT (Profit Before Depreciation and Tax) grew 29% to ₹232.81 crore from ₹180.05 crore in the previous year's corresponding quarter. As reported by Business Standard, PBT (Profit Before Tax) increased 30% to ₹212.22 crore compared to ₹162.99 crore in Q1 FY26, indicating strong operational performance across all profitability metrics during the quarter. The company's focus on APIs remains unchanged, with the strong financial performance supporting its position in the pharmaceutical API market.
For the full financial year 2026, Alivus Life Sciences demonstrated exceptional performance with standalone net profit climbing 16.24% to ₹564.48 crore on a 6.91% rise in revenue from operations to ₹2,551.83 crore compared to FY25. The company generated a strong free cash flow of ₹259 crore during FY26, leading to cash and cash equivalents of ₹782.4 crore as of March 31, 2026. According to management commentary, EBITDA margins of 33.6% were achieved, exceeding the guided range of 30-32%, driven by favorable product mix and disciplined cost control.
